Published in Cell Death Dis on March 23, 2017
Cancer statistics, 2016. CA Cancer J Clin (2016) 32.95
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov (2012) 26.98
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1996) 26.30
Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature (2013) 13.60
Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov (2009) 10.59
Renal-cell carcinoma. N Engl J Med (2005) 10.17
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature (2011) 7.94
X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res (2004) 6.22
Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol (2009) 3.41
Early development of polycystic kidney disease in transgenic mice expressing an activated mutant of the beta-catenin gene. Oncogene (2001) 2.63
Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer (2007) 2.00
Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res (2013) 2.00
Regulation of an activated S6 kinase 1 variant reveals a novel mammalian target of rapamycin phosphorylation site. J Biol Chem (2002) 1.66
The role of traditional Chinese herbal medicines in cancer therapy--from TCM theory to mechanistic insights. Planta Med (2010) 1.60
Oridonin induced autophagy in human cervical carcinoma HeLa cells through Ras, JNK, and P38 regulation. J Pharmacol Sci (2007) 1.43
Potential mechanism(s) involved in the regulation of glycogen synthesis by insulin. Mol Cell Biochem (1998) 1.39
Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett (2010) 1.25
Differential control of growth, cell cycle progression, and expression of NF-kappaB in human breast cancer cells MCF-7, MCF-10A, and MDA-MB-231 by ponicidin and oridonin, diterpenoids from the chinese herb Rabdosia rubescens. Biochem Biophys Res Commun (2005) 1.24
The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int J Oncol (2005) 1.17
Oridonin induces apoptosis and senescence in colorectal cancer cells by increasing histone hyperacetylation and regulation of p16, p21, p27 and c-myc. BMC Cancer (2010) 1.08
Intracellular glutathione depletion by oridonin leads to apoptosis in hepatic stellate cells. Molecules (2014) 1.08
Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility. J Med Chem (2013) 1.06
Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol (2014) 1.01
Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol (2015) 0.88
Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. Mol Cancer Ther (2012) 0.87
Molecular Insight in the Multifunctional Effects of Oridonin. Drugs R D (2015) 0.84
Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. Oncogene (2016) 0.83
Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target. Cancer Lett (2015) 0.83
Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by oridonin nanosuspension. Drug Deliv (2010) 0.83
Synthesis, characterization, in vitro and in vivo evaluation of PEGylated oridonin conjugates. Int J Pharm (2013) 0.80
Oridonin inhibits the proliferation of human osteosarcoma cells by suppressing Wnt/β-catenin signaling. Int J Oncol (2014) 0.80
Unsaturated Fatty Acids Stimulate Tumor Growth through Stabilization of β-Catenin. Cell Rep (2015) 0.79
A Novel Inhibitor of AKT1-PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo. Mol Cancer Ther (2015) 0.78
[Regulation of telomerase activity and cell cycle of K562 cells by oridonin]. Yao Xue Xue Bao (2004) 0.77
Non-canonical GLI1/2 activation by PI3K/AKT signaling in renal cell carcinoma: A novel potential therapeutic target. Cancer Lett (2015) 0.83
Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues. Oncotarget (2016) 0.77
DAB2IP regulates EMT and metastasis of prostate cancer through targeting PROX1 transcription and destabilizing HIF1α protein. Cell Signal (2016) 0.76
DAB2IP in cancer. Oncotarget (2016) 0.76
RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial-mesenchymal transition via MAPK/SOX2 pathway in bladder cancer. Cell Death Dis (2017) 0.75
The network of DAB2IP-miR-138 in regulating drug resistance of renal cell carcinoma associated with stem-like phenotypes. Oncotarget (2017) 0.75
2'-hydroxyflavanone inhibits prostate tumor growth through inactivation of AKT/STAT3 signaling and induction of cell apoptosis. Oncol Rep (2014) 0.75
The network of DAB2IP-miR-138 in regulating drug resistance of renal cell carcinoma associated with stem-like phenotypes. Oncotarget (2017) 0.75